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Introduction
Sterile α motif domain–containing protein 9 (SAMD9, OMIM 
610456) is a 1,589–amino acid protein that is encoded by a gene 
on the long arm of chromosome 7 (7q21.2) (1). SAMD9 has little 
homology to other proteins except for SAMD9L, also on 7q21.2, 
with which it shares 58% identity (1–3). SAMD9 and SAMD9L are 
likely to act as growth suppressors, and overexpression of SAMD9 
suppresses tumor progression in non–small cell lung cancer cells 
(4). In contrast, reduced SAMD9 expression has been reported in 
several tumor tissues, cisplatin chemoresistance, and normophos-
phatemic familial tumoral calcinosis (5–7). Similarly, loss of SAMD9 
and SAMD9L by monosomy 7 or monosomy 7q (–7/7q–) is well 
established in myeloid lineage malignancies (8, 9), and disruption 
of SAMD9L has been shown to be associated with the development 
of myelodysplastic syndrome (MDS) in mice and humans (10, 11). 
These growth-regulating effects are potentially mediated by altered 
endosomal degradation of the EGF receptor (EGFR) (10).
Three case reports of children with intrauterine growth 
restriction (IUGR), congenital adrenal insufficiency, gonadal 
failure, and monosomy 7 have been published in the last 20 years 
(12–14). These children also developed MDS, presumably sec-
It is well established that somatic genomic changes can influence phenotypes in cancer, but the role of adaptive changes 
in developmental disorders is less well understood. Here we have used next-generation sequencing approaches to 
identify de novo heterozygous mutations in sterile α motif domain–containing protein 9 (SAMD9, located on chromosome 
7q21.2) in 8 children with a multisystem disorder termed MIRAGE syndrome that is characterized by intrauterine growth 
restriction (IUGR) with gonadal, adrenal, and bone marrow failure, predisposition to infections, and high mortality. 
These mutations result in gain of function of the growth repressor product SAMD9. Progressive loss of mutated SAMD9 
through the development of monosomy 7 (–7), deletions of 7q (7q–), and secondary somatic loss-of-function (nonsense 
and frameshift) mutations in SAMD9 rescued the growth-restricting effects of mutant SAMD9 proteins in bone marrow 
and was associated with increased length of survival. However, 2 patients with –7 and 7q– developed myelodysplastic 
syndrome, most likely due to haploinsufficiency of related 7q21.2 genes. Taken together, these findings provide strong 
evidence that progressive somatic changes can occur in specific tissues and can subsequently modify disease phenotype 
and influence survival. Such tissue-specific adaptability may be a more common mechanism modifying the expression of 
human genetic conditions than is currently recognized.
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Results
SAMD9 mutations cause a multisystem growth restriction disorder. 
Eight patients with marked IUGR and severe testicular dysfunc-
tion leading to female external genitalia in six children and atypi-
cal (“ambiguous”) external genitalia in 2 children were referred to 
our centers for treatment and precise genetic analysis (Table 1). 
Testes were undescended in most (7 of 8) patients with preserved 
structure but decreased testosterone, where assessed (Figure 1A 
and Supplemental Tables 1 and 2; supplemental material available 
online with this article; https://doi.org/10.1172/JCI91913DS1). 
Neonatal-onset severe adrenal insufficiency was diagnosed in 6 
of 8 children, whereas 1 had mild adrenal dysfunction and another 
had normal adrenal function into adolescence (Figure 1A and Sup-
plemental Tables 1 and 2). All children were delivered preterm and 
were severely ill in the neonatal period and needed intensive care. 
Other features included severe pulmonary infections and a bron-
ondary to the monosomy 7, but the interrelation of these features 
was not understood.
Very recently, heterozygous gain-of-function mutations in 
SAMD9 have been reported in 11 patients with IUGR, adrenal 
insufficiency, and gonadal failure, together with bone marrow 
failure (15). Two of these patients had monosomy 7 and developed 
MDS. This condition has been termed MIRAGE syndrome (myelo-
dysplasia, infections, restriction of growth, adrenal hypoplasia, 
genital phenotypes, enteropathy) (OMIM 617053). Through dif-
ferent next-generation sequencing approaches we have simulta-
neously identified SAMD9 mutations in 8 patients with a complex 
multisystem growth restriction phenotype. Here we are able to 
show, for the first time to our knowledge, that complex dynamic 
somatic changes in SAMD9 and the SAMD9/SAMD9L locus on 
chromosome 7q occur, which are associated with this distinct dis-
ease phenotype and modify survival in these patients.
Table 1. Clinical and genetic findings in 8 patients with SAMD9 mutations
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7A Patient 8A
Progress Intrauterine death 
28 wk gestation
Died at 1 mo Died at 3 mo Died at 5 mo Died at 9 mo Died at 21 mo Alive  
(BMT at 6 mo)
Alive  
(BMT at 12 yr)
Karyotype 46,XY 46,XY 46,XY 46,XY 46,XY 46,XY 46,XY 46,XY
SAMD9: gain-of-
function mutationsB
p.Arg1293Gln, 
c.3878G>A,  
de novo
p.Arg982His, 
c.2945G>A,  
de novo
p.Arg982Cys, 
c.2944C>T,  
de novo
p.Arg459Gln, 
c.1376G>A,  
de novo
p.Arg982Cys, 
c.2944C>T,  
de novo
p.Arg685Gln, 
c.2054G>A,  
de novo
p.Lys1569Asn, 
c.4707G>T,  
de novo
p.Ile983Ser, 
c.2948T>G, no 
parental DNA
Age at delivery 28 wk (IUD) 28 wk 34 wk 31 wk 31 wk 32 wk 37 wk 36 wk
IUGR Yes Yes Yes Yes Yes Yes Yes Yes
BW (g)/SDS 464/–2.4 810/–1.8 1,194/–2.7 1,160/–1.6 880/–1.9 1,150/–1.7 1,680/–3.0 1,860/–2.5
Adrenal insufficiency n.a.; adrenal 
agenesis
Severe; adrenal 
agenesis
Severe; adrenal 
agenesis
Severe; adrenal 
agenesis
Severe Severe Mild No
Genital appearanceC Female Female Female Female “Ambiguous” Female Male with severe 
hypospadias
Female with slight 
clitoromegaly
Gonads Intraabdominal 
testes
Intraabdominal 
testes
Intraabdominal 
testes
Inguinal testes Inguinal testes Intraabdominal 
gonads
Descended testes Inguinal testes
BloodD
 Thrombocytopenia n.a. + + + – + Mild +
 Anemia n.a. + + + – + – –
 Infection/Sepsis n.a. Yes Yes Yes Yes Yes Yes Yes
Lung
 RDS/BPD n.a. Patchy CXR + + + + – +
Gastrointestinal
 Diarrhea/Infection n.a. – + + + + + +
Secondary changes in hematopoietic cells
Karyotype –7/7q– ND ND ND –7 –7 –7 then 7q– –7 7q–
Mutant allele (%) 
initial sample
53% 48% 49% 47% 47% 51% 28% 22%
Mutant allele (%) 
later sample
33% 13% 21%
SAMD9: secondary 
loss-of-function 
mutations
p.Lys27*,  
c.79A>T
p.Arg1533*, 
c.4597C>T
p.Arg344*, 
c.1030C>T
p.Asn765Thrfs*13, 
c.2294delA
APatients presented around the time of diagnosis of MDS. BAll DNA samples tested were obtained from blood leukocytes except patient 1 (liver) and 
patient 4 (late, bone marrow). CAssessment of genital appearance can be difficult in preterm growth-restricted babies. DOther variable features observed 
in some patients include small thymus, severe diaper rashes, frontal bossing, short phalanges, hydrocephalus, cerebellar hypoplasia, apneas, and reduced 
body fat. BMT, bone marrow transplantation; BPD, bronchopulmonary dysplasia; BW, birth weight; IUD, intrauterine death; IUGR, intrauterine growth 
restriction; n.a., not available; ND, not detected; RDS, respiratory distress syndrome; SDS, standard deviation score; –7, monosomy 7; 7q–, partial loss of the 
long arm of chromosome 7.
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mutations in the patients show clustering in a key hotspot, which 
is often reported in gain-of-function changes (16).
Immunohistochemistry of human fetal adrenal tissue showed 
generalized localization of SAMD9 in the cytoplasm of cells in 
the definitive and fetal zones, with strong expression in cells posi-
tive for the nuclear receptor NR5A1 (also known as steroidogenic 
factor 1, or SF-1) (Figure 2A). In the testis, SAMD9 was present in 
interstitial (Leydig) cells and seminiferous cords (Supplemental 
Figure 1). Using quantitative reverse transcriptase PCR of human 
fetal and adult tissues, SAMD9 expression was highest in the fetal 
adrenal gland, with high expression also in the colon, bone mar-
row, fetal liver, thymus, spleen, lung, liver, and fetal testis (Figure 
2B). This expression pattern correlates very well with the clinical 
phenotype seen in the patients (Table 1).
SAMD9 is a growth repressor, and SAMD9 mutations further 
reduce cell proliferation. Stable selection of HEK293 cells trans-
fected with SAMD9 mutant constructs was undertaken and cell 
proliferation studied. Transfection of WT SAMD9 resulted in 
decreased cell proliferation, consistent with a role for SAMD9 as 
a growth repressor (Figure 2C). Transfection of SAMD9 harboring 
the mutations found in our patients resulted in further repression 
of cell proliferation, consistent with the variants having a gain-
chopulmonary dysplasia–like phenotype requiring oxygen, recur-
rent and severe bacterial and viral infections, persistent diarrhea, 
severe diaper rashes, frontal bossing, hydrocephalus due to mem-
brane development induced by infections, and bone marrow fail-
ure (thrombocytopenia, anemia) (Table 1). Six of the children died 
in the first 2 years of life. Two children (patients 7 and 8) survived 
but developed MDS with monosomy 7 and received bone mar-
row transplantation (Table 1). Following written informed con-
sent from families, DNA samples were obtained from all patients, 
fibroblasts from 3 of them, and bone marrow cells from 2 to try to 
identify the underlying basis of this condition.
Using a combination of whole-exome sequencing and tar-
geted capture, heterozygous SAMD9 mutations were identified 
in all 8 children (Table 1 and Figure 1, B and C). These changes 
were de novo in all 7 children in whom parental DNA was avail-
able and were located in highly conserved residues, often affected 
arginines (6 of 8) with half of all mutations clustering in a hotspot 
of codons 982/983 (Figure 1, C and D). Although SAMD9 has 
many single nucleotide variations, the specific mutations identi-
fied in these children were not found in more than 100,000 alleles 
in public databases nor in more than 100 children with primary 
adrenal insufficiency and normal birth weight. Moreover, the 
Figure 1. Mutations in SAMD9 identified in 8 patients with IUGR and a multisystem disorder. (A) Adrenal and testis histology from patient 4. Top: Small 
islands of adrenal tissue (Ad) were identified in perinephric fat. Scale bar: 1 mm. Bottom: Testis showing rare Leydig cells (arrows) between seminiferous 
cords. Scale bar: 100 μm. (B) The location of SAMD9, SAMD9L, and HEPACAM2 on chromosome 7q21.2. (C) Mutations resulting in increased growth repres-
sion are shown in black. Acquired somatic loss-of-function mutations are shown in red. (D) Conservation of SAMD9 protein sequence in different species, 
with the position of mutated residues shown in red. Human SAMD9 is shown on top. Human SAMD9L is shown at the bottom.
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samples of these 3 patients and 
identified a reduced expression 
pattern compared with that of 
samples from 3 healthy control 
individuals (Figure 2E and Sup-
plemental Figure 2).
Progressive loss of chromo-
some 7 occurs in patients surviving 
beyond early infancy. Follow-up 
of patients surviving the first 3 
months of life showed that all 
of them had evidence of mono-
somy 7 (–7) or partial deletions 
of its long arm (7q–) (Table 1 and 
Figure 3A). Most importantly, by 
analyzing serial samples available 
in 3 patients by whole-genome 
array, we could demonstrate that 
–7/7q– was not present at early 
time points but these changes 
were acquired later (Figure 3A; 
patients 4–6). Furthermore, in the 
2 patients with MDS at the time of 
diagnosis, significant –7/7q– ratios 
were detected (patients 7 and 
8). By studying chromatogram 
profiles, single-nucleotide prim-
er extension assays, and DNA 
subcloning, we showed that the 
development of –7 removed the 
allele harboring the gain-of-func-
tion SAMD9 mutation (Table 1; 
Figure 3, A–C; and Supplemental 
Figures 3 and 4). Furthermore, in 
patient 6, bone marrow cells with 
–7 were predominant initially but 
were later replaced by cells with 
7q–, resulting in more specific 
removal of the locus containing 
the mutated SAMD9 (Figure 3B).
Demonstration of a dynamic 
evolution of secondary loss-of-func-
tion mutations in SAMD9 that res-
cue growth repression. In addition 
to the chromosomal changes iden-
tified, 4 children had evidence 
of somatic nonsense (stop gain) 
or frameshift (single nucleotide 
deletion) loss-of-function muta-
tions in SAMD9 in their hemato-
poietic compartment (Table 1 and 
Figure 1C). Two of these changes 
were not detected using standard Sanger sequencing, but were 
present in a proportion of deep sequencing reads (Figure 4A). All 
changes were confirmed and quantified using single-nucleotide 
primer extension assays and by subcloning and sequencing of 
PCR-amplified DNA (Figure 4B and Supplemental Figures 5 and 
of-function effect (Figure 2C). Cell proliferation assays were also 
performed in fibroblasts from 3 patients. These fibroblasts express 
the mutated alleles and showed significantly decreased prolifera-
tion in comparison with control cells (Figure 2D). Additionally, we 
analyzed the SAMD9 protein and mRNA expression in fibroblast 
Figure 2. SAMD9 is expressed in key tissues and represses cell growth. (A) Immunohistochemistry showing 
SAMD9 expression in human fetal adrenal gland at 9 weeks postconception (red) with NR5A1 (also known as 
steroidogenic factor 1) shown in green and DAPI-stained nuclei in blue. C, capsule; DZ, definitive zone; FZ, fetal 
zone. Scale bar: 100 μm. (B) SAMD9 expression in different human fetal and adult tissues showing high expres-
sion in fetal adrenal as well as in tissues affected in the clinical phenotype. Tissues especially relevant to the 
phenotype are highlighted (*). Data are shown as relative expression compared with GAPDH. Representative 
data are shown as mean ± SEM for a single study performed with triplicate technical replicates. Similar patterns 
were seen in independent studies using both GAPDH and ACTB as housekeeping genes. (C) Growth of HEK293 
cells was reduced following stable transfection of WT SAMD9 (mean ± SD; mock vs. WT, P < 0.001) and reduced 
further by the gain-of-function mutations found in patients (WT vs. samples, P < 0.0001, black bars). Data 
represent mean ± SD for the absolute cell number in 3 independent studies, each performed in triplicate  
(n = 9; 2-tailed t tests). (D) BrdU assays showing significantly reduced growth of patient fibroblasts (patients 4, 
6, and 8) compared with fibroblasts from 3 independent controls. Data represent mean ± SD cell proliferation for 
3 independent studies, each with 6 technical replicates (unless specified, n = 18; 1-way ANOVA with Tukey’s mul-
tiple comparison test, controls vs. patients, P < 0.001). (E) qRT-PCR analysis of fibroblast samples from 3 patients 
with a SAMD9 gene mutation revealed a significant reduction of gene expression compared with SAMD9 expres-
sion in fibroblasts derived from 3 healthy control individuals. Data represent mean ± SEM relative expression for 4 
independent studies, each with 2 replicates (Mann-Whitney test, controls vs. patients, P < 0.05).
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structures) was identified in 2 of the patient cell lines (patients 6 
and 8), as shown in representative images (Figure 6B) and in quan-
titative analysis of early endosome size (Figure 6, C and D).
Induced pluripotent stem cells containing SAMD9 mutations can 
be differentiated into intermediate mesoderm. In order to determine 
the effects of SAMD9 mutants on cellular differentiation and 
function, induced pluripotent stem cells (iPSCs) were generated 
from fibroblasts of 2 of the patients (patients 6 and 8). Cells har-
boring the primary gain-of-function SAMD9 mutations showed 
iPSC differentiation characteristics similar to those of controls 
based on pluripotency tests, stem cell markers, and hierarchical 
clustering of RNA expression data (Figure 7, A–C, and Supple-
mental Figure 8). Cells could be differentiated into intermediate 
mesoderm with profiles similar to those of control cells (Figure 
7C). Gene expression analysis of the cells followed by hierar-
chical clustering showed that patient-derived cells (fibroblasts, 
iPSCs, intermediate mesoderm) did cluster with each other and 
were distinct from control cells (Figure 7C). This finding likely 
represents an effect of the underlying SAMD9 mutation, poten-
tially influencing EGFR signaling and other biologically relevant 
pathways (e.g., urogenital development) (Supplemental Table 
3). Interestingly, apoptotic and inflammatory signals seem to be 
deregulated during mesoderm differentiation, suggesting that, in 
6). Functional studies were performed in HEK293 cells trans-
fected with SAMD9 containing the primary gain-of-function 
mutant together with the relevant loss-of-function change. These 
cells showed increased proliferation, suggesting that the growth-
repressing effects of gain-of-function mutations in SAMD9 can 
be “rescued” by these secondary loss-of-function changes (Fig-
ure 5, A and B).
These data show that the expression of the mutant SAMD9 
protein was abrogated in most children by more than 1 mecha-
nism. In patients 5, 7, and 8, –7/7q– occurred together with a loss-
of-function point mutation (Table 1). In patient 6, bone marrow 
cells showed progressive monosomic loss of the SAMD9 locus 
(Figure 3, B and C).
SAMD9 mutations produce subtle changes in early endosome size. 
Electron microscopy of patient fibroblasts compared with control 
cells showed that a small subpopulation of patient cells contained 
multiple large vesicles (>1.5 μm) as well as dilated endoplasmic 
reticulum and enlarged mitochondria, but these changes were 
heterogeneous, and extensive areas of cytoplasm containing large 
vesicles were not seen (Figure 6, A and B, and Supplemental Fig-
ure 7). No marked differences in late endosome structure were 
seen between patient and control fibroblasts (Figure 6B, green 
structures). A modest increase in the size of early endosomes (red 
Figure 3. Acquired loss of chromosome 7 (–7) and its long arm (7q–) occurred in association with a reduction in the gain-of-function SAMD9 mutations. 
(A) Chromatograms (top) from all 8 patients showing the SAMD9 mutations and a reduction in the mutant peak following development of monosomy 7 as 
shown by cytogenomic array (bottom). All samples are from peripheral leukocytes except the later sample in patient 4, which is from bone marrow DNA. 
Typical disomic chromosome 7 signal is shown in blue, whereas the signal with monosomy is shown in green. Data are presented in relation to length of 
survival. For patients 4–6 the earlier array is shown on the left and the later array on the right. The age at sampling is shown above the figure. BMT, bone 
marrow transplantation; IUD, intrauterine death; mo, months. (B) Serial cytogenetic data (leukocytes) from patient 6 showing the expansion of cells with 
–7 followed by their displacement by a 7q– clone removing the locus containing the SAMD9 gene. (C) Serial changes in the WT and mutant allele percent-
age (%) in patient 6 show that –7/7q– is associated with a reduction of the mutant SAMD9 allele, most likely due to the growth selection advantage of 
bone marrow cells that have lost the growth-repressing mutation. Data are derived from single-nucleotide primer extension assays for leukocyte DNA. A 
similar reduction in mutant allele was found in other patients who developed –7/7q– (patients 4 and 5) or who presented with a –7/7q– clone at the time of 
diagnosis of MDS (patients 7 and 8) (Table 1 and Supplemental Figures 3 and 4).
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addition to defective proliferation, excessive stress signals might 
also contribute to hematopoietic failure.
Discussion
Using a combination of whole-exome sequencing and targeted 
capture, we have identified a severe multisystem disorder caused 
by heterozygous SAMD9 mutations in eight 46,XY patients with 
marked IUGR, severe testicular dysfunction, congenital adre-
nal insufficiency, thrombocytopenia/anemia, persistent diar-
rhea, and severe infections resulting in a life-threatening course. 
Three children died in utero or in the first 3 months of life, 3 chil-
dren died between 3 months of age and 2 years, and 2 children 
were diagnosed with MDS and survived following bone marrow 
transplantation. Detailed studies in a panel of fetal and adult tis-
sues show that SAMD9 expression closely mirrors the features of 
the clinical syndrome.
An independent study has very recently reported a similar, 
though distinct, phenotype caused by SAMD9 mutations (15), 
characterized by IUGR, infections, enteropathy, adrenal hypopla-
sia, and underdeveloped external genitalia (MIRAGE syndrome) 
(15). Only 2 of the 11 patients reported had monosomy 7 and 
developed myelodysplasia. In contrast, all children in our study 
had a 46,XY karyotype, and significantly more marked gonadal 
dysfunction with female-appearing external genitalia in 6 of 
them, as well as other additional features such as hydrocephalus, 
cerebellar hypoplasia, small thymus, and short phalanges, and 
severe neonatal disease with higher mortality in early infancy. 
Therefore, this cohort represents a significantly different subset 
of the phenotypical spectrum. Although a small increase in early 
endosome size was seen in fibroblasts from 2 of our patients, as 
well as some enlarged vesicles and organelles, we were unable 
to detect the large late endosomes or large destructive vesicles 
described in the other report (15).
Whereas only 2 of the 11 patients reported by Narumi et al. had 
evidence of mosaic monosomy 7, 6 of the 8 patients in our cohort 
had evidence of complex and dynamic somatic events in hema-
topoietic cells that would be predicted to abrogate the growth-
repressing gain-of-function mutations in SAMD9.
Using several different approaches, it was possible to show 
consistently that the development of –7 removed the allele har-
boring the SAMD9 mutation. This has been termed “adaption by 
aneuploidy,” but examples of this phenomenon influencing dis-
ease mechanism in humans are so far limited to SAMD9/SAMD9L 
(11, 15). For the first time, to our knowledge, we are now able to 
Figure 4. Additional loss-of-function mutations occur-
ring in SAMD9. (A) Low-copy-number nonsense (stop 
gain) mutations were found in 2 infants who died in 
the first year of life (patients 3 and 5). These changes 
were not seen on chromatograms but were detected by 
deep sequencing and by subcloning of DNA amplicons 
and sequencing of 50–100 clones. Both patients with 
a milder phenotype (patients 7 and 8) had loss-of-
function mutations detected on chromatograms. A 
single nucleotide variant causing a nonsense muta-
tion was found in patient 7 (chromatogram and deep 
sequencing reads shown). A single nucleotide deletion 
(arrowhead) causing a frameshift was found in patient 
8. Control and patient forward sequence is shown in the 
upper panels and the patient’s reverse sequence shown 
below. Note: The reverse-direction nucleotide sequence 
is shown in the next-generation sequencing reads. 
Patient age at sampling is indicated. (B) Single-nucle-
otide primer extension assays confirming the WT and 
mutant allele percentage of additional SAMD9 loss-of-
function changes in the patients described above.
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show that the development of –7/7q– was progressive in 3 patients, 
with 1 child (patient 6) showing even complex dynamic cytogenet-
ic changes involving first –7 and then 7q– over time.
Furthermore, 4 children additionally had evidence of the 
development of somatic nonsense (stop gain) or frameshift (single 
nucleotide deletion) mutations in SAMD9 in their hematopoietic 
compartment. In the 2 children with the mildest phenotype, these 
somatic changes could be detected by traditional Sanger sequenc-
ing. However, 2 other children had evidence of second somatic 
loss-of-function changes that were only detected by deep sequenc-
ing and confirmed by single-nucleotide primer extension assays or 
by subcloning of PCR-amplified DNA. These changes would not 
have been detected by traditional sequencing approaches.
As a consequence of these events, the expression of the 
mutant SAMD9 protein progressively became abrogated in most 
children by more than 1 mechanism. These observations indicate 
that bone marrow cells that lost the mutated SAMD9 allele had a 
clonal advantage. The coexistence of different second-hit muta-
tions all affecting the mutated SAMD9 allele strongly suggests 
that the putative gain-of-function germline mutation imposed 
severe growth restriction on the hematopoietic system reflected 
by the clinical symptoms of the patients, who suffered from ane-
mia, thrombocytopenia, and infections from early infancy. As a 
consequence, the pressure of cells to lose the mutated SAMD9 
gene seemed to be exceptionally high. The genetic heterogeneity 
of bone marrow cells found in patients 5, 6, 7, and 8 gave evidence 
that a second hit occurred early and simultaneously in different 
hematopoietic stem and progenitor cells, all giving rise to clones 
with increased competitiveness (–7/7q–). However, this phenom-
enon was associated with the risk of malignant transformation. 
It has to be assumed that MDS in these patients was polyclonal 
rather than monoclonal, at least during the initial disease stages. 
Under certain circumstances and depending on the additional 
somatic hits, 1 single clone might have overgrown the others, as 
observed for the 7q– clone in patient 6. Therefore, the detection of 
multiple genomes in an individual might not only represent ran-
domly occurring events, but could also reflect clonal expansion 
of cells with deletions and loss-of-function mutations that have a 
selection and proliferation advantage over cells carrying deleteri-
ous gain-of-function changes.
The outcome (length of survival) seemed to correlate with 
the progressive development of –7/7q– and of second hits in the 
bone marrow. Notably, the 2 children (patients 7 and 8) with the 
mildest phenotypes had non-arginine primary mutations, large 
clones with –7 or 7q– present at time of diagnosis of MDS, and 
the highest somatic load of the additional nonsense or frameshift 
change. Therefore, –7 and the other second-hit changes affecting 
the SAMD9 locus provided a partial rescue of growth suppres-
sion, but paved the way for malignant transformation again limit-
ing survival. Early detection of SAMD9 mutations in patients with 
IUGR, adrenal and gonadal failure, and severe neonatal infec-
tions is important, because bone marrow transplantation may 
be necessary for survival. As all of the children in our study who 
could be tested (7 of 8) had de novo changes, it seems likely that 
recurrence would only occur if a parent carried a germline mosa-
icism. This has been reported to be the case in 1 patient (15). Fur-
thermore, SAMD9 has many single-nucleotide polymorphisms. 
Some of these have been shown to have no functional conse-
quence by Narumi et al. (15), so careful analysis of potential gain 
of function will be required.
Although the association between childhood MDS and –7/7q– 
is well established, the molecular basis of this condition has until 
Figure 5. Secondary loss-of-
function mutations “rescue” 
the growth-repressive effects 
of SAMD9 gain-of-function 
mutations. (A) The effects of 
the naturally occurring second-
ary nonsense or frameshift 
changes in the SAMD9 protein 
were studied in HEK293 cells 
in the same experiments as 
shown in Figure 2C. Addition 
of these secondary changes 
resulted in a loss of repressor 
activity (primary mutant vs. 
double mutant, all P < 0.0001, 
dark gray bars). Data represent 
mean ± SD for the absolute cell 
number in 3 independent stud-
ies, each performed in triplicate 
(n = 9; 2-tailed paired t test). 
(B) Representative images of 
cell density for the primary 
mutation (left column) and 
combined primary and second-
ary mutations (right column) 
for patients 3, 5, 7, and 8. Scale 
bars: 100 μm.
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that for SAMD9 is emerging, although it is so far not possible to 
define whether the primary cause of the malignant transformation 
is SAMD9L, SAMD9, or other genes in the locus.
In addition to the dynamic somatic changes, genomic regula-
tion of SAMD9 may also be important in controlling the balance 
of cell proliferation. By studying patient fibroblasts compared with 
controls, we were initially surprised to detect reduced SAMD9 
expression at both the RNA and protein levels. This finding may 
represent reduced transcriptional regulation of SAMD9 in the con-
text of a gain-of-function change. This hypothesis is supported by 
the report of increased SAMD9 mRNA in fibroblasts from patients 
with normophosphatemic familial tumoral calcinosis, a condition 
that occurs due to loss of SAMD9 function (7). Indeed, previous 
work has suggested that the SAMD9 promoter can be regulated 
by inflammatory cytokines such as TNF-α and IFN-γ (18, 19), so 
genomic regulation with possible feedback mechanisms might 
recently not been well understood, as many candidate tumor sup-
pressor genes have been identified on chromosome 7, and func-
tional losses of these genes have been implicated in disease initia-
tion and/or progression (9, 17). One putative tumor suppressor is 
the homolog of SAMD9, SAMD9L. SAMD9L and SAMD9, together 
with the HEPACAM2 gene, are located on 7q21.1 (Figure 1B), a 
region that has been found to be deleted in a subset of patients with 
myeloid leukemia and myelodysplastic syndromes (9). Although 
targeted deletion of Samd9l in the mouse results in myeloid neo-
plasia, the exact role of SAMD9L in transformation is still unclear 
(10). Very recently, heterozygous mutations causing a putative gain 
of function of the growth-suppressing effects of SAMD9L have 
been reported in human ataxia-pancytopenia syndrome (11). Two 
of these children developed myeloid malignancies, with evidence 
of monosomy 7 in the bone marrow or in derived cell lines from 
several of these patients. Therefore, a very similar mechanism to 
Figure 6. Analysis of the effect of SAMD9 mutations on cell structure and endosomes. (A) Electron microscopy of fibroblasts from controls and patients 
showed a modest increase in the number and size of cytoplasmic vesicles (V) and mildly dilated rough endoplasmic reticulum (ER) in a small subpopu-
lation of patient cells, but the effects were very heterogeneous (see also Supplemental Figure 7). Nu, nucleus. Scale bars: 2 μm. (B) Patient fibroblasts 
showing early endosomes (Rab5a, red) and late endosomes (Rab7a, green). Scale bars: 10 μm. (C) Early endosome volumes were greater in fibroblasts from 
patients 6 and 8 compared with controls, with greater variability in patients’ samples. Mean endosome volume for 10 independent cells was analyzed for 
each group. Data are shown as mean values with a whiskers plot to show the range (1-way ANOVA and Tukey’s post hoc test, P < 0.05). (D) A distribution 
analysis of early endosome volume for all cells studied also showed a shift toward larger early endosome volume for patients 6 and 8. Data are shown as 
mean ± SEM for 10 independent cells in each group. Mean number of endosomes quantified per cell, n = 2,248.
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nisms of developmental conditions. Future studies to try to dif-
ferentiate intermediate mesoderm, for example into adrenal-like 
cells, might be informative in revealing SAMD9-related effects, 
and potentially to study the development and effects of dynamic 
secondary somatic changes in a relevant in vitro model system.
Based on our observations, SAMD9 is a growth-restricting 
protein that plays a major role in the development of many sys-
tems and leads to intrauterine growth retardation but has a 
marked effect on adrenal gland and testes differentiation. A 
similar growth restriction condition causing adrenal hypoplasia is 
IMAGe syndrome, due to gain-of-function changes in the pater-
nally imprinted cell cycle regulator CDKN1C (20). Children with 
IMAGe syndrome also have prenatal growth restriction and adre-
nal insufficiency, but the gonadal phenotype seems less severe, 
and we are unaware of features such as enteropathies, bone mar-
row failure, or infections.
Immunohistochemistry of human fetal adrenal gland and testis 
showed widespread localization of SAMD9 in the cytoplasm of inter-
also serve to regulate cellular SAMD9 activity in the context of 
gain- or loss-of-function changes.
In order to study the underlying pathogenic basis of this con-
dition further, the effects of SAMD9 gain of function on the deri-
vation of iPSCs from fibroblasts, and subsequent differentiation 
of iPSCs into intermediate mesoderm, were studied in 2 of the 
patients (patients 6 and 8). iPSCs and intermediate mesoderm 
were successfully generated, suggesting that SAMD9 does not 
have a marked effect on early differentiation events. However, the 
patient samples did cluster together compared with the controls, 
suggesting changes in gene expression that may involve biologi-
cally relevant pathways. Indeed, RNA expression data revealed 
potential changes in developmental programs, general transcrip-
tion, and apoptotic and inflammatory signals, all pathways that 
possibly contribute to the developmental and bone marrow failure 
phenotype. Even though our results are preliminary, exploiting 
iPSC technology will provide potentially important disorder- and 
patient-specific model systems for further studying the mecha-
Figure 7. Effects of SAMD9 mutations on the derivation of fibroblasts into iPSCs and further differentiation into intermediate mesoderm. (A) PluriTest 
analysis of the array data. Undifferentiated patient-derived iPSCs fall within the empirically set thresholds for pluripotent cells. The plot shows that the 2 
patient lines (patients 6 and 8) and the normal control iPSC line cluster with pluripotent stem cells (red cloud) in contrast to the fibroblasts they originated 
from that cluster with partly reprogrammed or differentiated cells (blue clouds). Each circle represents 1 iPSC or fibroblast line. (B) iPSCs of both patients 
stained positive for the pluripotency markers NANOG, tumor rejection antigen 1-60 (TRA-1-60) (cell surface), stage-specific embryonic antigen 4 (SSEA4) 
(cell surface), and OCT3/4 (nuclear). Nuclei were counterstained with Hoechst 33342. Scale bars: 50 μm. (C) Hierarchical clustering of patient and control 
samples showing clustering by cell type (fibroblasts, iPSCs, intermediate mesoderm). Within each cell group, patient samples containing SAMD9 muta-
tions grouped together. Functional enrichment analysis using DAVID showed potential changes in biologically relevant pathways in the 2 patient samples 
compared with control samples in the different cell lines (Supplemental Table 3).
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gene, with complex changes far beyond just “adaption by aneu-
ploidy.” While somatic variability and adaptation are well stud-
ied in cancer, there is considerably less evidence to date for these 
changes influencing development and developmental disorders. 
Such somatic rescue mechanisms may be most evident in trophic 
systems with rapid turnover, such as the hematopoietic system. 
Here, we were able to detect these dynamic changes by analyz-
ing serial DNA samples from leukocytes. However, other dynamic 
systems might be subject to similar rescue mechanisms, but these 
changes would never be detected unless serial tissue samples 
were studied, which, in humans, is often challenging. For exam-
ple, the absence of an adrenal phenotype in patient 8 may have 
been due to an adrenal-specific rescue, but obtaining tissue for 
deep sequencing is not possible. Furthermore, in the presence of 
aneuploidy, evidence for the primary genetic “driver” may be lost, 
especially if Sanger sequencing is used. Consequently, dynamic 
somatic variation of the genome could be present more frequently 
than appreciated and might contribute to the variable penetrance 
of phenotypes and even reversibility of certain disorders at a tis-
sue level. Random loss-of-function events might be especially 
common modifiers when the primary driver is a gain-of-function 
change, such as shown here for SAMD9.
Methods
Patients and samples. DNA samples were obtained with permission 
from children referred primarily for the diagnosis of congenital 
adrenal insufficiency or morphological adrenal abnormalities. One 
baby had died in utero, and 1 child presented late and was included 
given the similarity of the phenotype and presence of monosomy 7. 
DNA samples were obtained from blood leukocytes at different time 
points using standard methods. Where documented in the article, 
DNA was also extracted from liver (postmortem), bone marrow, 
or fibroblasts. Parental DNA samples were obtained from blood or 
saliva for 7 of 8 children. The clinical characteristics of the cohort are 
shown in Table 1. Biochemical, endocrine, and cytogenetic investiga-
tions were undertaken using standard clinical protocols, and histol-
ogy of bone marrow, adrenal glands, gonads, and other tissues was 
confirmed by pathological review.
stitial (Leydig) cells and seminiferous cords, as reported in adults 
(http://www.proteinatlas.org/ENSG00000205413-SAMD9/ 
tissue) (21). In the testis, SAMD9 may have a greater effect on fetal 
Leydig cells during the critical early stages of development (6–12 
weeks postconception) than Sertoli cells, as testis structure and mor-
phology was relatively well preserved, most children had regression of 
Müllerian structures (which is dependent on anti-Müllerian hormone 
from Sertoli cells), and testosterone concentrations were generally 
lower than expected. The predominant fetal Leydig cell features are 
similar to the phenotype most commonly associated with disruption 
of NR5A1, which colocalizes with SAMD9 in many cells (22).
It is also emerging that during embryogenesis a fine balance 
between cell number and differentiation of cells is a prerequisite 
for normal organ development and size. Several models have 
been proposed for the adrenal gland and testis, whereby adequate 
proliferation of cells must occur prior to differentiation (23–26). 
Organ hypoplasia could result if inadequate proliferation occurs 
prior to differentiation, or if differentiation occurs too rapidly 
without sufficient proliferation or outside a critical window. We 
propose that SAMD9 is essential for controlling cell proliferation 
to maintain this balance (Figure 8). Gain-of-function mutations 
in SAMD9 might lead to a significant reduction of cells that could 
subsequently undergo differentiation/hyperplasia. In this con-
text it is important that SAMD9 has been lost during evolution 
in the mouse (5). We speculate that this may be one reason why 
mice are more resistant than humans to the disruptive effects of 
developmental regulators such as NR5A1 and DAX-1 (also known 
as NR0B1). Haploinsufficiency of NR5A1 and hemizygosity of 
DAX-1 cause profound gonadal and adrenal phenotypes, respec-
tively, in humans, but mice do not show such marked features (22, 
27–29). Thus mice may be able to adapt in these situations, as they 
do not have the growth-restrictive effects of SAMD9.
In addition to shedding light on SAMD9 and growth, this 
study clearly demonstrates, for the first time to our knowledge, 
that dynamic changes within the genome can influence develop-
mental mechanisms, phenotypes, and even outcome. More than 
half of the patients studied had evidence of chromosomal changes 
of the relevant genomic region and/or second mutations in the 
Figure 8. Schematic diagram showing the effects of SAMD9 on cell proliferation during development. During typical development, SAMD9 is a repressor 
that regulates controlled proliferation of cells (gray). Activation/gain-of-function (G-o-F) mutations in SAMD9 (pink) result in reduced proliferation of cells 
prior to differentiation, causing tissue hypoplasia. Secondary somatic changes in SAMD9 such as monosomy 7 (blue) or loss-of-function (L-o-F) mutations 
(green) remove the deleterious effect and allow partial rescue.
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(Thermo Fisher Scientific). RNA (2 μg) was reverse transcribed with 
the SuperScript III Reverse Transcription kit (Thermo Fisher Scientif-
ic) according to the manufacturer’s instructions. Quantitative reverse 
transcriptase PCR (qRT-PCR) was performed using the TaqMan Fast 
Advanced Master Mix (Applied Biosystems) and the SAMD9 TaqMan 
assay (Hs00539471_s1, Thermo Fisher Scientific), on the StepOnePlus 
System (Thermo Fisher Scientific). The relative expression of SAMD9 
was calculated as 2–ΔΔCt using the comparative Ct (ΔΔCt) method 
and GAPDH (Hs02758991_g1, Thermo Fisher Scientific) or ACTB 
(Hs99999903_m1, Thermo Fisher Scientific) as internal housekeep-
ing control. Experiments were repeated on 4 independent occasions, 
twice for each housekeeping gene. Representative data are shown for 
a single study performed with triplicate replicates.
For SAMD9 mRNA expression in fibroblasts, samples were studied 
from 3 healthy control individuals and 3 patient samples (patients 4, 6, 
and 8). RNA was extracted from 4 × 106 cells using the Trizol method. 
DNase digestion and cDNA synthesis were performed according to 
standard protocols (NEB, Promega). qRT-PCR reactions for SAMD9 
as well as the housekeeping genes ACTB and GAPDH were established 
according to standard protocols using an iCycler (Bio-Rad). Oligonu-
cleotide sequences are shown in Supplemental Table 4. Results repre-
sent 4 independent experiments each performed in 2 replicates. The 
results were analyzed using the ΔΔCt method, and statistical analysis 
was performed using the Mann-Whitney test.
Immunohistochemistry. Human fetal adrenal gland and testis tis-
sue (9 weeks postconception) was provided with approval from the 
HDBR. Following cryosection, tissue sections (12 μm) were fixed 
briefly in 4% paraformaldehyde in TBS, rinsed in TBS, and blocked 
in 1% BSA in TBS-Tween (0.5% Tween) for 1 hour before incubation 
overnight with mouse monoclonal anti–human SF-1 antibody (Invitro-
gen, N1665; 1:200 dilution) and rabbit polyclonal anti–human SAMD9 
antibody (Sigma-Aldrich, HPA021319; 1:200 dilution). Sections were 
washed in TBS-Tween and incubated for 1 hour with the relevant 
secondary antibodies: Alexa Fluor 488–goat anti-mouse (Invitrogen, 
A11001; 1:400) and Alexa Fluor 555–goat anti-rabbit (Invitrogen, 
A21429; 1:400), respectively. Nuclei were counterstained with DAPI 
(Sigma-Aldrich). Slides were washed with TBS and mounted using 
ProLong Gold Antifade Mountant (Life Technologies). Images were 
collected on a Zeiss LSM 710 confocal microscope (Carl Zeiss) and 
analyzed using Zeiss Zen 2009 and ImageJ (NIH).
Whole-genome array. Chromosomal microarray copy number 
analysis was performed on gDNA and analyzed versus a refer-
ence (Affymetrix Reference Model file created from microarrays 
using 284 HapMap samples representing Yoruba, Asian, and Cau-
casian ethnic groups and 96 samples from phenotypically healthy 
males and females). The DNA was digested with Nsp1, amplified, 
fragmented to 25–125 bp, and biotin-labeled before hybridization 
to Affymetrix Cytochip 750K arrays in a GeneChip Hybridiza-
tion Oven 645 in accordance with the manufacturer’s instructions 
(user’s guide; Cytoscan Assay Rev 4, Affymetrix). The microarrays 
were washed and stained in a GeneChip Fluidics Station 450 and 
scanned using a GeneChip Scanner 3000 (Affymetrix). Raw data 
were processed in Chromosome Analysis Suite v2 (Affymetrix) and 
examined using the high-resolution setting providing an estimated 
practical resolution of 200 kb.
Single-nucleotide primer extension reactions. Primers were designed 
to flank the specific patient mutations and sequence variants (Supple-
Whole-exome sequencing and analysis. Five micrograms of genomic 
DNA (gDNA) was enriched using the Agilent Human All Exon V4 kit 
(Agilent Technologies) following the manufacturer’s protocol. Whole-
exome libraries were sequenced on an Illumina HiSeq 2000 system 
for 1x101 cycles following the manufacturer’s instructions (Illumi-
na). All raw sequencing reads were mapped onto UCSC hg19 using 
BWA 0.5.9-r16, and mappings were converted into BAM file format 
using SAMtools (v0.1.18). Initial mappings were postprocessed using 
Genome Analysis Toolkit (GATK) 1.3-21 following the “best practices 
V3.” In brief, reads were realigned around sites of known insertions 
and deletions (INDELs), and likely PCR duplicates were detected 
using Picard 1.48. Finally, raw base quality scores were empirically 
recalibrated. Single-nucleotide polymorphisms (SNPs) and short 
INDELs were identified using the UnifiedGenotyper from GATK and 
in parallel with the variant caller in SAMtools. Variants were classified 
as novel or known variants deposited in dbSNP 135. Functional conse-
quences of each variant were annotated using snpEff 2.0.5d for UCSC 
hg19 RefSeq genes and ENSEMBL 65 human gene models. The poten-
tial deleterious effect was evaluated using PolyPhen 2, SIFT, PhyloP, 
MutationTaster, GERP++, LRT, and OMIM if available. Candidate 
variants from GATK and from SAMtools were compared to increase 
both sensitivity and specificity.
Targeted next-generation sequencing panel. A HaloPlex DNA tar-
geted gene enrichment panel (Agilent Technologies) was designed 
using SureDesign software (www.agilent.com/genomics/suredesign) 
to capture all coding exons and 100 bp of intronic flanking sequence 
of genes of interest. The entire custom design covered 160 genes 
involved in adrenal development and function, for a total size of 
497.956 kbp. The total number of amplicons was 21,612 with predicted 
target coverage of 98.7%. gDNA samples (225 ng each) were prepared 
for Illumina sequencing according to the HaloPlex Target Enrichment 
System protocol (version D.5, Agilent Technologies) (30). Libraries 
were sequenced on the Illumina MiSeq platform following the manu-
facturer’s instructions (Illumina). FAST-Q files were analyzed using 
SureCall (v3.0.1.4) software (Agilent Technologies).
Variant analysis and validation. To confirm the presence and 
identity of the variants, Sanger sequencing was performed on PCR 
amplicons from gDNA covering the variant position. Direct sequenc-
ing was carried out using Big Dye Terminator v1.1 Cycle Sequencing 
Kit (Applied Biosystems) on an ABI 3130 sequencer (Applied Biosys-
tems) and visualized using Sequencher v5.2.4 (Gene Codes Corp.). 
Novel missense variants were absent in at least 100 control samples 
with adrenal insufficiency and normal birth weight and in population 
control databases such as the Exome Aggregation Consortium (ExAC) 
browser (Cambridge, Massachusetts, USA; http://exac.broadinstitute.
org; accessed November 2015).
Sequence alignment. Multiple sequence alignments of SAMD9 were 
generated using Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/).
Quantitative reverse transcriptase PCR. A human total RNA panel 
comprising several tissue sources (catalog 636643, Clontech Labora-
tories) was used to study the expression of SAMD9. The panel includ-
ed brain, cerebellum, kidney, adrenal gland, lung, placenta, skeletal 
muscle, spleen, testis, thymus, uterus, fetal brain, and fetal liver. In 
addition, RNA from human fetal adrenal gland and testis (9 weeks 
postconception), provided with approval from the Human Develop-
mental Biology Resource (HDBR, www.hdbr.org), was used. Puri-
fied RNA was quantified using a NanoDrop 1000 spectrophotometer 
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lumi-light plus Western blotting substrates (Roche). Four independent 
Western blotting experiments were performed.
Assay for cell proliferation. Fibroblast proliferation was evaluated 
using a Cell Proliferation ELISA BrdU colorimetric kit (Roche Diag-
nostics). Cells were cultured in DMEM supplemented with 0.2% FBS 
and 1% penicillin/streptomycin at 37°C in a humidified atmosphere 
(5% CO2) for 6 days. Thereafter, 1.5 × 104 cells were seeded in 96-well 
plates, and after 24 hours BrdU solution (10 μM) was added and cells 
were incubated for an additional 24 hours. The incorporation of BrdU 
into the DNA was quantified according to the manufacturer’s proto-
col. Three independent experiments were performed, each with 6 
technical replicates, and 1-way ANOVA with Tukey’s multiple com-
parison test was used to compare proliferation of patient cells against 
controls. For 1 experiment, we failed to obtain reads for control 1 and 
2 technical replicates for patients 4 (sample 2) and 6; therefore the 
number of replicates for those samples is different (control 1, n = 12; 
patients 4 and 6, n = 16).
Electron microscopy. The cellular ultrastructural morphology of 
cultured skin fibroblasts was examined from 3 affected individu-
als and 2 controls. Cells were pelleted, fixed in 2.5% glutaraldehyde 
followed by 1% osmium tetroxide, and then processed into agar 100 
resin. Sections (90 nm) were cut and stained with uranyl acetate and 
lead citrate. Ultrathin sections were examined using a JEOL 1400 
transmission electron microscope (JEOL). Independent images from 
20 randomly selected control or patient fibroblasts were studied.
Endosome studies. Fibroblasts were grown on a sterile tissue cul-
ture dish with a cover glass bottom (FD35-100, FluoroDish, World 
Precision Instruments) and were cotransfected with the RFP-Rab5a–
expressing vector and the GFP-Rab7a–expressing vector (CellLight 
Late Endosomes-GFP, Life Technologies). Live cells were imaged 48 
hours after transfection using a Zeiss LSM 710 confocal microscope 
(Carl Zeiss) and analyzed using Zeiss Zen 2009 and ImageJ (NIH). 
For quantitative studies of early endosome volume, fibroblasts were 
cotransfected with the RFP-Rab5a vector as above, and after 48 hours 
culture medium was removed and cells were washed with PBS. Cells 
were fixed for 20 minutes with 4% paraformaldehyde in PBS at room 
temperature, and then washed 3 times with PBS. Ten images/cells 
per patient and control were collected using a Zeiss LSM 710 confo-
cal microscope (Carl Zeiss). Deconvolution of raw images was carried 
out using Huygens Software (Scientific Volume Imaging); endosome 
volume was measured using Imaris Software (Bitplane). Statistical 
analysis was performed in Prism (GraphPad), using 1-way ANOVA and 
Tukey’s post hoc test (P < 0.05). These studies were done in a blind 
fashion by the investigator.
Reprogramming. Reprogramming of patient and control fibro-
blasts was performed using Sendai virus vectors (CytoTune-iPS 2.0 
Reprogramming Kit, Thermo Fisher Scientific). In brief, 5 × 104 cells 
were seeded in 1 well of a 24-well plate and cultured in proliferation 
medium that consisted of DMEM supplemented with 10% FCS, 1× 
GlutaMAX with 100 U/ml penicillin, and 100 μg/ml streptomycin 
(all from Thermo Fisher Scientific). Cells were transduced using the 3 
Sendai polycistronic vectors KLF4–OCT3/4–SOX2, c-Myc, and KLF4 
(CytoTune-iPS 2.0 Sendai Reprogramming Kit, Thermo Fisher Scien-
tific). After addition of the virus, the plate was centrifuged at 800 g 
for 20 minutes at room temperature. On the next day, medium was 
exchanged with fresh proliferation medium. Cells were cultured for 
7 days with medium changes every other day. On day 8 after transduc-
mental Table 5). After treatment with shrimp alkaline phosphatase 
and exonuclease I, PCR products were used in single-nucleotide 
primer extension reactions using the ABI Prism SNaPshot Multiplex 
kit (Applied Biosystems) and appropriate specific 35-mer forward 
primers to detect the nucleotide at the position of interest. After 
removal of unincorporated dideoxynucleotides (ddNTPs), the fluores-
cently labeled single-stranded DNAs were analyzed on the ABI 3730 
sequencer (Applied Biosystems) together with the GeneScan 500 
ROX dye size standard. Relative proportions of alleles were derived 
from the peak areas in the electropherograms. In pilot experiments, 
allele ratios were compared for PCR reactions conducted between 24 
and 30 cycles to ensure that alleles were being independently ampli-
fied. For subsequent analyses, PCRs were run for 28 cycles.
Subcloning studies. Validation of low-copy-number variants 
and quantification of mutations were also performed by subclon-
ing of DNA and screening of multiple independent colonies. In 
brief, gDNA from patients was PCR-amplified with a high-fidelity 
Taq polymerase, Elongase (Life Technologies). PCR products were 
ligated into the pCR-XL-TOPO vector and transformed into One 
Shot TOP10 chemically competent cells (Life Technologies). Plas-
mid DNA was extracted and the region of interest sequenced, as 
described above. Between 50 and 100 independent clones were 
studied in each experiment.
Functional studies of SAMD9 WT and mutant activity. A pCMV6-
Entry vector containing human SAMD9 cDNA was obtained from Ori-
gene (SC304503). All 7 single and 4 double SAMD9 mutations were 
introduced into the cDNA by site-directed mutagenesis using the 
Quik Change Multi Site-Directed Mutagenesis Kit (Agilent Technolo-
gies), and well as the 4 secondary changes alone (total n = 15). All vec-
tors were sequenced to validate the mutations.
For functional studies of cell proliferation, 2 × 105 HEK293 cells 
(ATCC CRL-1573) were transfected with the pCMV6-Entry vector 
with the 17 different SAMD9 variants (15 mutants, WT, or empty vec-
tor) using Lipofectamine 3000 (Thermo Fisher Scientific) following 
the manufacturer’s protocol. All cells were negative for mycoplasma. 
Stably transfected cells were selected with G418 (500 μg/ml) (Gibco) 
for 14 days and collected once the controls reached confluence. Repre-
sentative images of cell density were taken by bright-field microscopy 
using an Olympus 1X71 inverted microscope. Cells were trypsinized, 
pelleted, and resuspended before being counted on a FACSCalibur 
sorter (BD Biosciences) using propidium iodide to exclude dead cells. 
Experiments were performed in triplicate on 3 independent occasions. 
Results are presented as mean (SD) for all 3 studies. These studies 
were all performed in a blind fashion by the investigator.
Fibroblasts. Skin fibroblasts from patients 4, 6, and 8 and from 2 con-
trols were grown in DMEM supplemented with 10% FBS and 1% peni-
cillin/streptomycin at 37°C in a humidified atmosphere (5% CO2). All 
fibroblast cultures used were negative for mycoplasma contamination.
Western blot analysis. Total protein lysates from fibroblast cultures 
(passage 2–5; 4 μg) were transferred with a semidry electrophoretic 
method according to standard protocols on a PVDF membrane (Perkin-
Elmer). The membrane was blocked with 5% nonfat dry milk in 0.03% 
PBS-Tween and sequentially incubated with anti-SAMD9 (Sigma- 
Aldrich, HPA021319) and anti–α-tubulin Clone B-5-1-2 (Sigma- 
Aldrich, T5168) antibodies. As a second antibody, polyclonal goat/
anti-rabbit IgG–HRP (DAKO, P0448) and anti-mouse IgG–peroxi-
dase (Roche, 12015218001) were used. Bands were visualized with 
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Expression profiling. Total RNA was isolated using the RNeasy Kit 
(Qiagen) from the 2 patient iPSC lines (patients 6 and 8) and the con-
trol iPSC line (control 1), as well as from the primary fibroblasts these 
lines were derived from. In addition, RNA was isolated from the 2 
patient intermediate mesoderm cell lines (patients 6 and 8) and 2 con-
trol intermediate mesoderm cell lines (controls 1 and 2). Biotin-labeled 
cRNA was generated using the Illumina TotalPrep RNA Amplification 
Kit (Ambion, USA) with 300 ng of quality-checked total RNA as input. 
cRNA samples were hybridized on HumanHT-12 v4 Expression Bead-
Chips (Illumina). Data analysis was performed using Genome Studio 
Software v2011.1 (Illumina) and Bioconductor (32). Functional enrich-
ment analysis was performed using DAVID (http://david.abcc.ncifcrf.
gov). Validation of pluripotency was carried out via the Web-based 
PluriTest open access software, a bioinformatics assay of pluripotency 
in human cells based on gene expression profiles (33).
Statistics. Statistical analysis was performed using GraphPad 
Prism and is described in the relevant sections. Student’s t tests were 
2-tailed. A P value less than 0.05 was considered significant. Microar-
ray data were analyzed using Bioconductor.
Data availability. All relevant data are available from the authors 
upon request. Microarray data are available through ArrayExpress 
(https://www.ebi.ac.uk/arrayexpress/) (accession code E-MTAB-5145).
Study approval. Written informed consent of the parents was 
obtained for research and diagnosis prior to inclusion in the study (UK 
IRB 07/Q0508/24; HDBR 08/H0712/34+35).
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tion, cells were passaged using TrypLE Select (Thermo Fisher Scien-
tific) and seeded with a density of 3 × 104 cells per well in proliferation 
medium onto a 6-well plate coated with Geltrex (Thermo Fisher Scien-
tific). On the next day, medium was changed to Essential 8 (E8) medi-
um (Thermo Fisher Scientific) supplemented with 100 U/ml penicillin 
and 100 μg/ml streptomycin. The E8 medium was replaced every day 
until human iPSC colonies appeared. Individual colonies were picked 
using a pipette tip and expanded in E8 medium on plates coated with 
Geltrex. Cell lines generated from the 2 patients are named CUBi001-
A (patient 6) and CUBi002-B (patient 8). Detailed information on the 
generated cell lines is available in the Human Pluripotent Stem Cell 
Registry (https://hpscreg.eu/).
Culture of iPSCs. The iPSCs were cultured in E8 medium supple-
mented with 100 U/ml penicillin and 100 μg/ml streptomycin in 
6-well dishes coated with Geltrex and routinely passaged using 0.5 
mM EDTA (Thermo Fisher Scientific) in PBS (without calcium and 
magnesium) every 5–7 days at a splitting ratio of about 1:20. The iPSC 
lines BIHi001-A (control 1) and BIHi004-A (control 2) (both lines 
derived from fibroblasts of healthy donors) were used as controls in 
the differentiation and gene expression analysis experiments. Details 
of these lines are available at https://hpscreg.eu/. 
Immunofluorescence staining for pluripotency markers. For stain-
ing, iPSCs were grown in 96-well imaging plates (CellCarrier, Perkin-
Elmer) in E8 medium. After 3 days, cells were fixed with Cytofix 
reagent, followed by blocking and permeabilization with PermWash 
reagent (both from BD Biosciences). Then, cells were incubated with 
the dye-conjugated antibodies anti–TRA-1-60–Vio488 (Miltenyi Bio-
tec, REA157, 130-106-872), anti-SSEA4–PerCP-Vio700 (Miltenyi 
Biotec, REA101, 130-105-053), anti-OCT3/4 (Isof. A)–APC (Miltenyi 
Biotec, REA338, 130-105-555), and anti-NANOG (D73G4)–PE (Cell 
Signaling Technology, 14955). Nuclei were stained with Hoechst 
33342 (2.5 μg/ml in PBS; Invitrogen). Images were captured using an 
Operetta high-content imaging system (PerkinElmer).
Karyotyping of iPSCs. Karyotyping was carried out using Karyo-
Lite BoBs (PerkinElmer). From each sample at least 240 ng of gDNA 
was used as a starting material. The samples were processed accord-
ing to the manufacturer’s instructions. Briefly, gDNA was labeled with 
biotin, purified, and hybridized to beads with complementary BAC 
probes. After washing and reporter (streptavidin-PE) binding, the 
fluorescent signals were measured with a Bio-Plex 200 system (Bio-
Rad). Results were analyzed using BoBsoft analysis software (Perkin-
Elmer). As references, female and male gDNA (Promega) was used. A 
sample was defined as “normal disomic” when the fluorescent ratio 
was approximately 1.0 for all loci analyzed.
Differentiation of iPSCs into intermediate mesoderm cells. iPSCs 
were differentiated into intermediate mesodermal cells using a pro-
tocol described by Lam et al. (31). iPSCs were harvested as single cells 
using Accutase (Thermo Fisher Scientific) and 4 × 105 cells seeded 
in each well of a Geltrex-coated 6-well plate in E8 medium. Medium 
was changed after 3 days to advanced RPMI, 1× GlutaMAX (both from 
Thermo Fisher Scientific), 5 μM CHIR99021 (Reagents Direct), 100 
U/ml penicillin, and 100 μg/ml streptomycin for 36 hours. For the next 
72 hours, the differentiation medium was changed to advanced RPMI, 
1′ GlutaMAX, 100 ng/ml bFGF (PeproTech), 2 μM retinoic acid (Milt-
enyi Biotec), 100 U/ml penicillin, and 100 μg/ml streptomycin. The 
cells were harvested using Accutase, and total RNA for gene expres-
sion analysis was extracted as described above.
Downloaded from http://www.jci.org on May 23, 2017.   https://doi.org/10.1172/JCI91913
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 7 1 3jci.org   Volume 127   Number 5   May 2017
WC’s present address is: Department of Biology; and Medi-X 
Institute, SUSTech Academy for Advanced Interdisciplinary Stud-
ies; Southern University of Science and Technology, Shenzhen, 
Guangdong, China.
Address correspondence to: John C. Achermann, Genetics and 
Genomic Medicine, UCL Great Ormond Street Institute of Child 
Health, 30 Guilford Street, London WC1N 1EH, United Kingdom. 
Phone: 44.207.905.2887; E-mail: j.achermann@ucl.ac.uk.
 1. Lemos de Matos A, Liu J, McFadden G, Esteves 
PJ. Evolution and divergence of the mammalian 
SAMD9/SAMD9L gene family. BMC Evol Biol. 
2013;13:121.
 2. Li Q, et al. Mouse Samd9l is not a functional para-
logue of the human SAMD9, the gene mutated in 
normophosphataemic familial tumoral calcino-
sis. Exp Dermatol. 2012;21(7):554–556.
 3. Jiang Q, et al. The Samd9L gene: transcrip-
tional regulation and tissue-specific expres-
sion in mouse development. J Invest Dermatol. 
2011;131(7):1428–1434.
 4. Ma Q, Yu T, Ren YY, Gong T, Zhong DS. Over-
expression of SAMD9 suppresses tumorigen-
esis and progression during non small cell 
lung cancer. Biochem Biophys Res Commun. 
2014;454(1):157–161.
 5. Li CF, et al. Human sterile alpha motif domain 
9, a novel gene identified as down-regulated in 
aggressive fibromatosis, is absent in the mouse. 
BMC Genomics. 2007;8:92.
 6. Wu L, et al. miR-96 induces cisplatin chemoresis-
tance in non-small cell lung cancer cells by down-
regulating SAMD9. Oncol Lett. 2016;11(2):945–952.
 7. Topaz O, et al. A deleterious mutation in SAMD9 
causes normophosphatemic familial tumoral 
calcinosis. Am J Hum Genet. 2006;79(4):759–764.
 8. Asou H, et al. Identification of a common micro-
deletion cluster in subband among patients 
with myeloid leukemia and myelodysplastic 
syndrome. Biochem Biophys Res Commun. 
2009;383(2):245–251.
 9. Honda H, Nagamachi A, Inaba T. -7/7q- syn-
drome in myeloid-lineage hematopoietic malig-
nancies: attempts to understand this complex 
disease entity. Oncogene. 2015;34(19):2413–2425.
 10. Nagamachi A, et al. Haploinsufficiency of 
SAMD9L, an endosome fusion facilitator, 
causes myeloid malignancies in mice mimicking 
human diseases with monosomy 7. Cancer Cell. 
2013;24(3):305–317.
 11. Chen DH, et al. Ataxia-Pancytopenia Syndrome 
is caused by missense mutations in SAMD9L. Am 
J Hum Genet. 2016;98(6):1146–1158.
 12. Le SQ, Kutteh WH. Monosomy 7 syndrome asso-
ciated with congenital adrenal hypoplasia and 
male pseudohermaphroditism. Obstet Gynecol. 
1996;87(5 pt 2):854–856.
 13. Olshanskaya YV, Udovichenko AI, Kolosova LY, 
Kokhno AV. Myelodysplastic syndrome with 
monosomy 7 in a patient with XY gonadal dys-
genesis (incomplete testicular feminization). 
Cancer Genet Cytogenet. 2009;191(2):113–114.
 14. McDonald S, et al. Acquired monosomy 7 myelo-
dysplastic syndrome in a child with clinical 
features suggestive of dyskeratosis congenita 
and IMAGe association. Pediatr Blood Cancer. 
2010;54(1):154–157.
 15. Narumi S, et al. SAMD9 mutations cause a novel 
multisystem disorder, MIRAGE syndrome, and 
are associated with loss of chromosome 7. Nat 
Genet. 2016;48(7):792–797.
 16. Wu TF, Yao YL, Lai IL, Lai CC, Lin PL, Yang WM. 
Loading of PAX3 to mitotic chromosomes is 
mediated by arginine methylation and associ-
ated with Waardenburg Syndrome. J Biol Chem. 
2015;290(33):20556–20564.
 17. Hasle H, Niemeyer CM. Advances in the prog-
nostication and management of advanced MDS 
in children. Br J Haematol. 2011;154(2):185–195.
 18. Chefetz I, et al. Normophosphatemic familial 
tumoral calcinosis is caused by deleterious muta-
tions in SAMD9, encoding a TNF-alpha responsive 
protein. J Invest Dermatol. 2008;128(6):1423–1429.
 19. Hershkovitz D, et al. Functional characterization 
of SAMD9, a protein deficient in normophospha-
temic familial tumoral calcinosis. J Invest Derma-
tol. 2011;131(3):662–669.
 20. Arboleda VA, et al. Mutations in the PCNA-bind-
ing domain of CDKN1C cause IMAGe syndrome. 
Nat Genet. 2012;44(7):788–792.
 21. Uhlén M, et al. Proteomics. Tissue-based 
map of the human proteome. Science. 
2015;347(6220):1260419.
 22. Lin L, et al. Heterozygous missense mutations in 
steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are 
associated with 46,XY disorders of sex develop-
ment with normal adrenal function. J Clin Endo-
crinol Metab. 2007;92(3):991–999.
 23. Ishimoto H, Jaffe RB. Development and func-
tion of the human fetal adrenal cortex: a key 
component in the feto-placental unit. Endocr Rev. 
2011;32(3):317–355.
 24. Svingen T, Koopman P. Building the mammalian 
testis: origins, differentiation, and assembly 
of the component cell populations. Genes Dev. 
2013;27(22):2409–2426.
 25. Lalli E, Sassone-Corsi P. DAX-1, an unusual 
orphan receptor at the crossroads of steroido-
genic function and sexual differentiation. Mol 
Endocrinol. 2003;17(8):1445–1453.
 26. Scheys JO, Heaton JH, Hammer GD. Evidence 
of adrenal failure in aging Dax1-deficient mice. 
Endocrinology. 2011;152(9):3430–3439.
 27. Suntharalingham JP, Buonocore F, Duncan 
AJ, Achermann JC. DAX-1 (NR0B1) and ste-
roidogenic factor-1 (SF-1, NR5A1) in human 
disease. Best Pract Res Clin Endocrinol Metab. 
2015;29(4):607–619.
 28. Bland ML, et al. Haploinsufficiency of steroido-
genic factor-1 in mice disrupts adrenal develop-
ment leading to an impaired stress response. Proc 
Natl Acad Sci U S A. 2000;97(26):14488–14493.
 29. Yu RN, Ito M, Saunders TL, Camper SA, Jameson 
JL. Role of Ahch in gonadal development and 
gametogenesis. Nat Genet. 1998;20(4):353–357.
 30. Guran T, et al. Rare causes of primary adrenal 
insufficiency: genetic and clinical characteriza-
tion of a large nationwide cohort. J Clin Endocri-
nol Metab. 2016;101(1):284–292.
 31. Lam AQ, Freedman BS, Morizane R, Lerou PH, 
Valerius MT, Bonventre JV. Rapid and efficient 
differentiation of human pluripotent stem cells 
into intermediate mesoderm that forms tubules 
expressing kidney proximal tubular markers.  
J Am Soc Nephrol. 2014;25(6):1211–1225.
 32. Gentleman RC, et al. Bioconductor: open soft-
ware development for computational biology and 
bioinformatics. Genome Biol. 2004;5(10):R80.
 33. Müller FJ, et al. A bioinformatic assay for 
pluripotency in human cells. Nat Methods. 
2011;8(4):315–317.
Downloaded from http://www.jci.org on May 23, 2017.   https://doi.org/10.1172/JCI91913
